Long-Term Follow-Up of Children in the HIVNET 012 Perinatal HIV Prevention Trial: Five-Year Growth and Survival.

Publication Type:

Journal Article


Journal of acquired immune deficiency syndromes (1999), Volume 64, Issue 5, p.464-71 (2013)


2013, November 2013, Vaccine and Infectious Disease Division


To describe 5-year growth, survival, and long-term safety among children exposed to nevirapine or zidovudine in an African perinatal prevention trial, HIVNET 012.